HEARTPUMP The Multi-Heart Plate: a human engineered mini-heart platform for functional cardiac disease modelling and drug testing
- Coordinator
- Universiteit Twente, Netherlands
- Runs
- 1 December 2026 to 31 May 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335553
What the project is doing
In the project's own words, from its summary on CORDIS.
Cardiovascular diseases remain a leading cause of mortality worldwide, yet drug development is hampered by the lack of predictive human models that capture cardiac function. In particular, diastolic dysfunction and heart failure with preserved ejection fraction represent major unmet medical needs, partly because current preclinical models inadequately reproduce human cardiac physiology. This HEARTPUMP project aims to explore the innovation potential of the Multi-Heart Plate (MHP), a novel human stem cell-based platform developed in the ERC Advanced Grant HEART2BEAT.
The MHP consists of miniature engineered cardiac chambers capable of pumping fluid and generating quantitative functional readouts such as cardiac output, ejection fraction and relaxation kinetics. This enables direct assessment of cardiac performance and drug responses in a physiologically relevant human model. HEARTPUMP will combine technical validation and commercial feasibility activities. Technically, we will demonstrate the reproducibility and robustness of the platform, develop and validate a diastolic dysfunction disease model, and establish a drug screening portfolio to benchmark predictive performance against existing models.
Workflow optimization, including automated data analysis and assay standardization will further improve scalability and usability for drug discovery. In parallel, we will engage with pharmaceutical and biotechnology companies and contract research organizations to assess industry requirements and obtain early feedback. Intellectual property strategy and market analysis will be conducted with technology transfer experts to evaluate commercial opportunities and guide the development of a business plan.
Together, these activities will demonstrate the technical and commercial feasibility of the MHP platform and establish the basis for its translation into cardiovascular drug discovery, potentially through creation of a spin-out company or alternative commercialization pathways.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Twente | Enschede | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI